Back to News
Market Impact: 0.38

Headed Into Earnings, Nike Stock Is Trading Lower Than It Was a Decade Ago. But Is the Turnaround Finally Working?

Corporate EarningsCorporate Guidance & OutlookConsumer Demand & RetailTax & TariffsTrade Policy & Supply ChainCapital Returns (Dividends / Buybacks)Company FundamentalsManagement & Governance
Headed Into Earnings, Nike Stock Is Trading Lower Than It Was a Decade Ago. But Is the Turnaround Finally Working?

Nike’s North America sell-through improved across all channels in February for the first time in two years, but Greater China revenue is expected to fall about 20% in the current quarter and gross margin was pressured by roughly 3 percentage points from higher U.S. tariffs. Fiscal Q3 net income fell 35% and gross margin slipped to 40.2% from about 41.5% a year ago, though management expects margins to improve later in fiscal 2027. The stock trades around 30x earnings and is down sharply, leaving investors dependent on a successful turnaround.

Analysis

The setup is becoming a classic regional divergence trade: North America is transitioning from inventory digestion to demand recovery, while Greater China is being intentionally throttled to rebuild pricing power. That is constructive for future gross margin quality, but it also means near-term reported revenue can stay noisy even if the underlying brand is healing. The market is likely underestimating how much of the China decline is a deliberate P&L tradeoff rather than cyclical demand loss, which matters because it should compress volatility in gross profit later in the turnaround.

The bigger second-order issue is supply chain reconfiguration under tariffs. If tariff pressure persists, Nike has limited ability to offset it quickly without either sacrificing margin or accelerating price increases into a still-fragile consumer backdrop. That makes the next two quarters a margin credibility test: any disappointment in North America sell-through or any delay in China full-price improvement would force the market to re-rate the recovery timeline, not just the multiple.

Consensus appears too focused on whether the business is 'cheap' versus whether earnings can compound from here. At ~30x earnings, the stock already discounts a decent recovery, so the asymmetry is in execution: if margins stabilize by early FY27 as guided, the stock can work; if not, the dividend only softens the drawdown. The more interesting contrarian angle is that the sell-off may have created a tradable floor for operational improvement, but not yet a durable long-term value case until investor day gives a cleaner bridge from inventory normalization to earnings growth.